COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance
Medical device company CooperCompanies (NASDAQ:COO) missed Wall Street’s revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion. The company’s full-year revenue guidance of $4.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.7% above analysts’ consensus estimates.
Is now the time to buy COO? Find out in our full research report (it’s free for active Edge members).
CooperCompanies (COO) Q2 CY2026 Highlights:
- Revenue: $1.07 billion vs analyst estimates of $1.10 billion (flat year on year, 2.9% miss)
- Adjusted EPS: $1.15 vs analyst estimates of $1.12 (2.7% beat)
- The company dropped its revenue guidance for the full year to $4.24 billion at the midpoint from $4.30 billion, a 1.5% decrease
- Management lowered its full-year Adjusted EPS guidance to $4.53 at the midpoint, a 1.9% decrease
- Operating Margin: 20.8%, up from 16.6% in the same quarter last year
- Organic Revenue rose 1% year on year (miss)
- Market Capitalization: $12.38 billion
StockStory’s Take
CooperCompanies faced a difficult Q2, with revenue growth constrained by proactive U.S. channel inventory reductions in its vision segment, muted performance in China, and a flat topline relative to last year. Management attributed underwhelming results primarily to these inventory actions, which they believe were necessary to reset the business for future growth. CEO Albert White described the quarter as one focused on “proactively reducing U.S. channel inventory,” which weighed on reported revenue, while underlying demand in the U.S. remained healthy. Management also pointed to strong cash generation and favorable outcomes in a long-standing tax matter as partial offsets to the operational challenges.
Looking forward, CooperCompanies’ reduced guidance is rooted in several ongoing headwinds, including continued inventory normalization in the U.S. and investments aimed at revitalizing sales execution and product launches. Management highlighted plans to expand sales coverage, enhance marketing, and accelerate new product introductions, particularly in the vision business. CFO Brian Andrews cautioned that near-term margin pressure is likely as the company ramps up commercial investments and faces ongoing foreign exchange and tariff headwinds. CEO White stated, “The sales force execution, this additional marketing, the intensity around that kind of stuff and targeting and so forth, is the key to success for us.”
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to actions taken to address inventory buildups, as well as the conclusion of a strategic review that influenced capital allocation and operational priorities.
- U.S. inventory reduction: CooperCompanies undertook significant inventory reductions in its U.S. vision business, citing the need to address elevated distributor stock levels resulting from private label contract wins and prior purchasing ahead of price changes. This action depressed near-term reported revenue, but management expects it will enable healthier growth in future periods as sales return to being consumption-driven.
- Strategic review outcome: The company concluded a comprehensive strategic review, ultimately deciding to retain CooperSurgical following what it described as a disconnect between internal valuations and market offers. Management highlighted recent competitive developments in non-hormonal IUDs and a fertility litigation settlement as factors that weighed on bids. The review resulted in an intensified focus on driving organic growth and disciplined capital allocation.
- Sales force and execution gaps: CEO White acknowledged CooperCompanies’ commercial execution lagged contract wins and product portfolio expansion, particularly due to a smaller sales force compared to peers. The company is now investing in sales coverage and commercial capabilities, especially in the Americas and Asia Pacific, aiming to improve conversion of contract wins into revenue growth.
- Product portfolio and R&D acceleration: The MyDay family, particularly toric and multifocal lenses, continued to see strong consumption growth, while legacy hydrogels were phased out. Management is accelerating new product development, with a focus on higher-value, premium offerings and plans to pull forward launches initially slated for later years.
- Cash flow strength and capital returns: Despite operational pressures, CooperCompanies generated record free cash flow, enabling $339 million in share repurchases this quarter. The board approved an additional $1 billion for repurchases, reflecting ongoing commitment to capital returns while maintaining leverage below 2x.
Drivers of Future Performance
Looking ahead, management expects a gradual return to revenue growth as inventory actions conclude, while margin headwinds persist from increased commercial investments and external pressures.
- Normalization of inventory and sales execution: The company anticipates that finishing inventory reductions and ramping up its sales force will set the stage for growth more in line with market consumption patterns, particularly in the Americas. Management believes enhanced commercial execution and better conversion of contract wins will be central to achieving mid-single-digit growth rates in the future.
- Margin and cost pressures: Ongoing investments in marketing, sales, and new product development are expected to weigh on operating margins in the near term. CFO Andrews noted that commercial expansion, foreign exchange headwinds, and lower tariff refunds would impact both gross and operating margins over the next quarter.
- Product innovation and market mix: CooperCompanies is accelerating the launch of new premium products, such as MyDay toric multifocal and MyDay Energys, to capture growth in higher-value segments. The company is also focusing on revitalizing underperforming markets, like Asia Pacific and China, through tailored product and channel strategies.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) how quickly CooperCompanies completes U.S. inventory normalization and whether sales growth aligns with consumption trends, (2) evidence that expanded sales force and marketing initiatives are converting contract wins into sustained revenue growth, and (3) progress in accelerating product launches and gaining traction in premium lens categories. Ongoing performance in fertility and the effectiveness of tailored strategies in China will also be key factors to monitor.
CooperCompanies currently trades at $54.44, down from $63.48 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.